7-44145515-A-T
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PP4_ModeratePM2_SupportingPP2PP3PP1PM1PM5
This summary comes from the ClinGen Evidence Repository: The c.1235T>A variant in the glucokinase gene, GCK, causes an amino acid change of valine to glutamic acid at codon 412 (p.(Val412Glu)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.988, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 2 unrelated individuals with hyperglycemia; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (PMID:30245511, internal lab contributors). One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate, PMID:30245511). This variant segregated with hyperglycemia with 2 informative meiosis 2 families (PP1; PMID:30245511, internal lab contributors). Another missense variant, c.1235 p.Val412Ala, has been interpreted as pathogenic by the ClinGen MDEP, and p.Val412Glu has a greater Grantham distance (PM5). In summary, c.1235T>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM1, PM5, PP2, PP3, PP4_Moderate, PM2_Supporting, PP1. LINK:https://erepo.genome.network/evrepo/ui/classification/CA367398282/MONDO:0015967/086
Frequency
Consequence
NM_000162.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Monogenic diabetes Pathogenic:1
The c.1235T>A variant in the glucokinase gene, GCK, causes an amino acid change of valine to glutamic acid at codon 412 (p.(Val412Glu)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.988, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in 2 unrelated individuals with hyperglycemia; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (PMID: 30245511, internal lab contributors). One of these individuals had a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate, PMID: 30245511). This variant segregated with hyperglycemia with 2 informative meiosis 2 families (PP1; PMID: 30245511, internal lab contributors). Another missense variant, c.1235 p.Val412Ala, has been interpreted as pathogenic by the ClinGen MDEP, and p.Val412Glu has a greater Grantham distance (PM5). In summary, c.1235T>A meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM1, PM5, PP2, PP3, PP4_Moderate, PM2_Supporting, PP1. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.